Interleukin-8, a promising predictor for prognosis of pancreatic cancer

Chen, Ying; Shi, Min; Yu, Guanzhen; Qin, Xiaoran; Jin, Gang; Chen, Peng; Zhu, Minghua

doi:10.3748/wjg.v18.i10.1123

Cited by 96 publications

(83 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the development of potential biomarkers for these tumors is an urgent unmet need. We also observed that patients with higher IL8 levels presented decreased survival, in accordance with previous reports (25)(26)(27)29,31,(42)(43)(44). Although this fact may be explained by tumor burden, a contribution by a direct pathogenic role of IL8 cannot be excluded, because IL8 is involved in tumor vascularization (5,45) and chemotactically disorients migration of immune cells (12).…”

Section: Discussionsupporting

confidence: 79%

“…22), urothelial tumors (23,24), hepatocellular carcinoma (HCC; refs. 25,26), colorectal cancer (27), gastric cancer (28), pancreatic cancer (29), ovarian cancer (30), breast cancer (31), neurologic tumors (32), lymphoma (33,34), and others (5,35) are available, but its value as a cancer biomarker to predict changes in tumor burden and to monitor response to cancer treatment has been poorly explored.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

Sanmamed

Carranza-Rua

Alfaro

et al. 2014

Clinical Cancer Research

202

158

View full text Add to dashboard Cite

Purpose: Interleukin-8 (IL8) is a chemokine produced by malignant cells of multiple cancer types. It exerts various functions in shaping protumoral vascularization and inflammation/immunity. We evaluated sequential levels of serum IL8 in preclinical tumor models and in patients to assess its ability to estimate tumor burden.Experimental Design: IL8 levels were monitored by sandwich ELISAs in cultured tumor cells supernatants, tumor-xenografted mice serum, and in samples from 126 patients with cancer. We correlated IL8 serum levels with baseline tumor burden and with treatment-induced changes in tumor burden, as well as with prognosis.Results: IL8 concentrations correlated with the number of IL8-producing tumor cells in culture. In xenografted neoplasms, IL8 serum levels rapidly dropped after surgical excision, indicating an accurate correlation with tumor burden. In patients with melanoma (n ¼ 16), renal cell carcinoma (RCC; n ¼ 23), non-small cell lung cancer (NSCLC; n ¼ 21), or hepatocellular carcinoma (HCC; n ¼ 30), serum IL8 concentrations correlated with tumor burden and stage, survival (melanoma, n ¼ 16; RCC, n ¼ 23; HCC, n ¼ 33), and objective responses to therapy, including those to BRAF inhibitors (melanoma, n ¼ 16) and immunomodulatory monoclonal antibodies (melanoma, n ¼ 8). IL8 concentrations in urine (n ¼ 18) were mainly elevated in tumors with direct contact with the urinary tract.Conclusions: IL8 levels correlate with tumor burden in preclinical models and in patients with cancer.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Introductionmentioning

confidence: 99%

Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

Sanmamed

Carranza-Rua

Alfaro

et al. 2014

Clinical Cancer Research

202

158

View full text Add to dashboard Cite

show abstract

“…28 The levels of MIP-1a and MCP-1 were higher in the longer surviving group and increased further after CRLX101 treatment. IFN- also increased after CRLX-101 treatment.…”

Section: Accepted M Manuscript 14mentioning

confidence: 92%

Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer

Gaur

Wang

Kretzner

et al. 2014

Nanomedicine: Nanotechnology, Biology and Medicine

View full text Add to dashboard Cite

“…Interleukin 8, a proinflammatory marker of CXC chemokine family, was found to be more commonly expressed in PDAC (55.6%) compared to para-cancer pancreatic tissue (25.9%), and CP (0%) and was found to predict the prognosis of PDAC [54]. Combination of CA 19-9 with various other biomarkers has been studied, such as CA 19-9, albumin, and insulin-like growth factor-1, or CA 19-9 with C-reactive protein and interleukin 8, or CA 19-9 with carcinoembryonic antigen and tissue inhibitor of metalloproteinase, but none of them has been found to be diagnostic [55][56][57].…”

Section: Laboratory Investigationsmentioning

confidence: 99%

Diagnosis and Management of Pancreatic Adenocarcinoma in the Background of Chronic Pancreatitis: Core Issues

Narkhede

Desai

Prasad

et al. 2019

Dig Dis

View full text Add to dashboard Cite

Background: The incidence of pancreatic adenocarcinoma (PDAC) in patients with chronic pancreatitis (CP) is as high as 5%. It is a commonly encountered diagnostic challenge in patients with CP on long-term follow-up. Summary: This review consolidates the existing literature on assessment of PDAC in background of CP, its evaluation through the available investigations, surgical management, and prognostication. Recent change in symptomatology of an otherwise stable CP should raise a suspicion of malignancy. Endoscopic ultrasound (EUS) is more specific and sensitive in establishing the diagnosis of PDAC compared to cross-sectional imaging (computed tomography/magnetic resonance imaging). Intraoperative assessment with careful palpation coupled with careful clinical judgment helps in differentiating between an inflammatory mass and pancreatic cancer. Confirmation can be obtained with either preoperative EUS-guided fine needle cytology/core biopsy or intraoperative core biopsy under ultrasound guidance. However, despite complete evaluation with above options, 1–6% patients often show malignancy on final histopathological examination. Key Messages: Diagnosis of PDAC in CP needs a high index of suspicion. Cross-sectional imaging has poor negative predictive value. CA 19-9 with MUC5AC combination may become an ideal investigation. EUS with core biopsy/frozen section has a good sensitivity and specificity and low false negative results. Complete radical resection should be the aim to get long-term survival.

show abstract

Interleukin-8, a promising predictor for prognosis of pancreatic cancer

Abstract: IL-8 can be a fine serum marker for predicting the prognosis pancreatic cancer.

Cited by 96 publications

References 27 publications

Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer

Diagnosis and Management of Pancreatic Adenocarcinoma in the Background of Chronic Pancreatitis: Core Issues

Contact Info

Product

Resources

About